Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer
Abstract Prostate cancer (PCa) is a non-cutaneous malignancy in males with wide variation in incidence rates across the globe. It is the second most reported cause of cancer death. Its etiology may have been linked to genetic polymorphisms, which are not only dominating cause of malignancy casualtie...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-023-03084-5 |
| _version_ | 1797451392154075136 |
|---|---|
| author | Khurram Rehman Zoya Iqbal Deng Zhiqin Hina Ayub Naseem Saba Muzammil Ahamd Khan Liang Yujie Li Duan |
| author_facet | Khurram Rehman Zoya Iqbal Deng Zhiqin Hina Ayub Naseem Saba Muzammil Ahamd Khan Liang Yujie Li Duan |
| author_sort | Khurram Rehman |
| collection | DOAJ |
| description | Abstract Prostate cancer (PCa) is a non-cutaneous malignancy in males with wide variation in incidence rates across the globe. It is the second most reported cause of cancer death. Its etiology may have been linked to genetic polymorphisms, which are not only dominating cause of malignancy casualties but also exerts significant effects on pharmacotherapy outcomes. Although many therapeutic options are available, but suitable candidates identified by useful biomarkers can exhibit maximum therapeutic efficacy. The single-nucleotide polymorphisms (SNPs) reported in androgen receptor signaling genes influence the effectiveness of androgen receptor pathway inhibitors and androgen deprivation therapy. Furthermore, SNPs located in genes involved in transport, drug metabolism, and efflux pumps also influence the efficacy of pharmacotherapy. Hence, SNPs biomarkers provide the basis for individualized pharmacotherapy. The pharmacotherapeutic options for PCa include hormonal therapy, chemotherapy (Docetaxel, Mitoxantrone, Cabazitaxel, and Estramustine, etc.), and radiotherapy. Here, we overview the impact of SNPs reported in various genes on the pharmacotherapy for PCa and evaluate current genetic biomarkers with an emphasis on early diagnosis and individualized treatment strategy in PCa. |
| first_indexed | 2024-03-09T14:54:00Z |
| format | Article |
| id | doaj.art-2e8af9a5da91438e9ff3a551cf48a30c |
| institution | Directory Open Access Journal |
| issn | 1475-2867 |
| language | English |
| last_indexed | 2024-03-09T14:54:00Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj.art-2e8af9a5da91438e9ff3a551cf48a30c2023-11-26T14:18:34ZengBMCCancer Cell International1475-28672023-10-0123112010.1186/s12935-023-03084-5Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancerKhurram Rehman0Zoya Iqbal1Deng Zhiqin2Hina Ayub3Naseem Saba4Muzammil Ahamd Khan5Liang Yujie6Li Duan7Faculty of Pharmacy, Gomal UniversityDepartment of Orthopedics, The First Affiliated Hospital of Shenzhen University, Second People’s HospitalDepartment of Orthopedics, The First Affiliated Hospital of Shenzhen University, Second People’s HospitalDepartment of Gynae, Gomal Medical CollegeDepartment of Gynae, Gomal Medical CollegeInstitute of Biochemistry and BiotechnologyDepartment of Child and Adolescent Psychiatry, Shenzhen Kangning Hospital, Shenzhen Mental Health CenterDepartment of Orthopedics, The First Affiliated Hospital of Shenzhen University, Second People’s HospitalAbstract Prostate cancer (PCa) is a non-cutaneous malignancy in males with wide variation in incidence rates across the globe. It is the second most reported cause of cancer death. Its etiology may have been linked to genetic polymorphisms, which are not only dominating cause of malignancy casualties but also exerts significant effects on pharmacotherapy outcomes. Although many therapeutic options are available, but suitable candidates identified by useful biomarkers can exhibit maximum therapeutic efficacy. The single-nucleotide polymorphisms (SNPs) reported in androgen receptor signaling genes influence the effectiveness of androgen receptor pathway inhibitors and androgen deprivation therapy. Furthermore, SNPs located in genes involved in transport, drug metabolism, and efflux pumps also influence the efficacy of pharmacotherapy. Hence, SNPs biomarkers provide the basis for individualized pharmacotherapy. The pharmacotherapeutic options for PCa include hormonal therapy, chemotherapy (Docetaxel, Mitoxantrone, Cabazitaxel, and Estramustine, etc.), and radiotherapy. Here, we overview the impact of SNPs reported in various genes on the pharmacotherapy for PCa and evaluate current genetic biomarkers with an emphasis on early diagnosis and individualized treatment strategy in PCa.https://doi.org/10.1186/s12935-023-03084-5SNPsAndrogen metabolismPharmacotherapyBiomarkersProstate cancerGenetic polymorphism |
| spellingShingle | Khurram Rehman Zoya Iqbal Deng Zhiqin Hina Ayub Naseem Saba Muzammil Ahamd Khan Liang Yujie Li Duan Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer Cancer Cell International SNPs Androgen metabolism Pharmacotherapy Biomarkers Prostate cancer Genetic polymorphism |
| title | Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer |
| title_full | Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer |
| title_fullStr | Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer |
| title_full_unstemmed | Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer |
| title_short | Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer |
| title_sort | analysis of genetic biomarkers polymorphisms in adme related genes and their impact on pharmacotherapy for prostate cancer |
| topic | SNPs Androgen metabolism Pharmacotherapy Biomarkers Prostate cancer Genetic polymorphism |
| url | https://doi.org/10.1186/s12935-023-03084-5 |
| work_keys_str_mv | AT khurramrehman analysisofgeneticbiomarkerspolymorphismsinadmerelatedgenesandtheirimpactonpharmacotherapyforprostatecancer AT zoyaiqbal analysisofgeneticbiomarkerspolymorphismsinadmerelatedgenesandtheirimpactonpharmacotherapyforprostatecancer AT dengzhiqin analysisofgeneticbiomarkerspolymorphismsinadmerelatedgenesandtheirimpactonpharmacotherapyforprostatecancer AT hinaayub analysisofgeneticbiomarkerspolymorphismsinadmerelatedgenesandtheirimpactonpharmacotherapyforprostatecancer AT naseemsaba analysisofgeneticbiomarkerspolymorphismsinadmerelatedgenesandtheirimpactonpharmacotherapyforprostatecancer AT muzammilahamdkhan analysisofgeneticbiomarkerspolymorphismsinadmerelatedgenesandtheirimpactonpharmacotherapyforprostatecancer AT liangyujie analysisofgeneticbiomarkerspolymorphismsinadmerelatedgenesandtheirimpactonpharmacotherapyforprostatecancer AT liduan analysisofgeneticbiomarkerspolymorphismsinadmerelatedgenesandtheirimpactonpharmacotherapyforprostatecancer |